Zymeworks (NASDAQ:ZYME - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report issued on Saturday.
Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Zymeworks in a research note on Wednesday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of "Sell".
Check Out Our Latest Research Report on ZYME
Zymeworks Trading Up 6.7%
NASDAQ ZYME opened at $18.06 on Friday. The company's 50-day simple moving average is $15.16. Zymeworks has a 12-month low of $9.03 and a 12-month high of $18.35. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -18.62 and a beta of 1.51.
Zymeworks (NASDAQ:ZYME - Get Free Report) last posted its quarterly earnings results on Tuesday, November 8th. The company reported ($1.14) earnings per share (EPS) for the quarter. The business had revenue of $4.40 million for the quarter. Zymeworks had a negative net margin of 59.96% and a negative return on equity of 21.59%.
Zymeworks Company Profile
(
Get Free Report)
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zymeworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymeworks wasn't on the list.
While Zymeworks currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
